OptiBiotix Health PLC New appointments
19 Gennaio 2021 - 08:00AM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
19 January 2021
Opti B i otix Health plc
( "Opti Bi o t ix" or "the Company")
New appointments
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high choleste
r ol and diabetes, announces the appointment of Dr Taru Jain as
Business Development Director in Asia and Christopher Nother , as
the pharmaceutical lead on LP(LDL) (R).
Christopher Nother is joining OptiBiotix on a part time
consultancy basis to support the growth of LP(LDL) (R) in pharma,
either as an 'over the counter' (OTC) product used by itself or in
combination with existing treatments (e.g. statins), or a drug
biotherapeutic in markets outside the USA. Chris joins OptiBiotix
after leading global business development at Nypro Healthcare's
(now Jabil Healthcare) Pharmaceutical Delivery Systems division.
Jabil Healthcare describes itself as the world's leading healthcare
contract manufacturing organisation on its website, and its parent
company, Jabil Inc., is a Fortune 200 world leading manufacturing
solutions provider. Chris advises a number of other businesses in
the healthcare and drug delivery systems sectors and is Interim CEO
at Surgical Synergy Limited.
Dr Taru Jain will join OptiBiotix's management team in March
2021 to focus on business development and growing sales in the
strategically important Indian and Asian markets. Dr. Taru was
previously the Executive Director at Akums Drugs &
Pharmaceuticals Ltd, (Akums website states it is India's single
largest Contract Research and Manufacturing (CRAMS) organisation
responsible for manufacturing approximately 11-12% of all drugs
consumed in the country). Her responsibilities at Akums included
in-licensing worldwide, marketing strategy and design, client and
account relationship management, along with representation of the
company on national and international forums. She has over 10 years
of experience across the Indian healthcare value chain as well as
primary knowledge of the demand pattern of the prescription and OTC
market.
Stephen OHara CEO of OptiBiotix Health plc c o m mented:
"OptiBiotix made strong progress last year in growing sales and
reducing costs and enters 2021 with a strong balance sheet and lead
pipeline. The Company is now focused on the next stage of its
development: growing sales and profitability in its divisions, and
commerciali s ing its next generation products (e.g. microbiome
modulators, SweetBiotix, and drug biotherapeutics).
" We now have more opportunities across a broader range of areas
that can effectively be commercialised with the size of the current
team. Chris and Taru bring additional capacity, expertise and a
network of contacts in product areas and markets of strategic
interest which will support future revenue growth. These
appointments are consistent with our strategy of developing
multiple revenue streams from both consumer and pharmaceutical
products across all OptiBiotix technology platforms."
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI) is a biotechnology company
formed in March 2012 which brings science and human studies to the
development of compounds which modify the human microbiome - the
collective genome of the microbes in the body - in order to prevent
and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients,
supplements, and potentially drug biotherapeutic products. More
than seventy international food and healthcare supplement companies
have signed agreements with OptiBiotix to incorporate their human
microbiome modulators into a wide range of supplements, food,
dairy, and beverage products.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRASFFFWAEFSEIF
(END) Dow Jones Newswires
January 19, 2021 02:00 ET (07:00 GMT)
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Mar 2023 a Mar 2024